Research Article Details

Article ID: A10322
PMID: 31388398
Source: World J Hepatol
Title: Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions.
DOI: 10.4254/wjh.v11.i7.562